European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio
Executive Summary
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.
You may also be interested in...
Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.
Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.